Monitoring Tolerance, Safety and Acceptance of Depo-Eligard in an Open Label, Retrospective, Non-Interventional Clinical Trial.
Phase of Trial: Phase IV
Latest Information Update: 10 Jun 2014
At a glance
- Drugs Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Astellas Pharma
- 10 Jun 2017 Biomarkers information updated
- 23 Jan 2010 Actual patient number (140) added as reported by ClinicalTrials.gov.
- 23 Jan 2010 Actual end date (Dec 2009) added as reported by ClinicalTrials.gov.